Collaborative Innovation in Drug Discovery / Wiley Series on Technologies for the Pharmaceutical (PDF)

Can academia save the pharmaceutical industry?

The pharmaceutical industry is at a crossroads. The urgent need
for novel therapies cannot stem the skyrocketing costs and
plummeting productivity plaguing R&D, and many key products are
facing patent expiration. Dr. Rathnam Chaguturu presents a case for
collaboration between the pharmaceutical industry and academia that
could reverse the industry's decline. Collaborative
Innovation in Drug Discovery: Strategies for Public and Private
Partnerships provides insight into the potential synergy
of basing R&D in academia while leaving drug companies to turn
hits into marketable products. As Founder and CEO of
iDDPartners, focused on pharmaceutical innovation, Founding
president of the International Chemical Biology Society, and Senior
Director-Discovery Sciences, SRI International, Dr. Chaguturu has
assembled a panel of experts from around the world to weigh in on
issues that affect the two driving forces in medical
advancement.

* Gain global perspectives on the benefits and potential issues
surrounding collaborative innovation

* Discover how industries can come together to prevent another
"Pharma Cliff"

* Learn how nonprofits are becoming the driving force behind
innovation

* Read case studies of specific academia-pharma partnerships for
real-life examples of successful collaboration

* Explore government initiatives that help foster cooperation
between industry and academia

Dr. Chaguturu's thirty-five years of experience in
academia and industry, managing new lead discovery projects and
forging collaborative partnerships with academia, disease
foundations, nonprofits, and government agencies lend him an
informative perspective into the issues facing pharmaceutical
progress. In Collaborative Innovation in Drug Discovery:
Strategies for Public and Private Partnerships, he and his
expert team provide insight into the various nuances of the
debate.